Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis

被引:1
|
作者
Lee, Ji Yae [1 ]
Kim, Sue [2 ]
Lee, Yaeji [3 ]
Kwon, Yu-Jin [4 ]
Lee, Ji-Won [1 ,5 ]
机构
[1] Yonsei Univ, Severance Hosp, Coll Med, Dept Family Med, Seoul 03722, South Korea
[2] Yonsei Univ Hlth Syst, Severance Hosp, Int Hlth Care Ctr, Seoul 03722, South Korea
[3] Yonsei Univ, Dept Biostat & Comp, Seoul 03722, South Korea
[4] Yonsei Univ, Yongin Severance Hosp, Coll Med, Dept Family Med, Yongin 16995, South Korea
[5] Yonsei Univ, Severance Hosp, Dept Family Med, Coll Med,Inst Innovat Digital Healthcare, Yonsei Ro 50-1, Seoul 03722, South Korea
基金
新加坡国家研究基金会;
关键词
Mediterranean diet adherence; steatotic liver disease; metabolic dysfunction-associated steatotic liver disease; alcohol-related liver disease; CARDIOVASCULAR-DISEASE; HEPATIC STEATOSIS; GUIDELINE; BENEFITS; NOMENCLATURE; NUTRITION; HEALTH;
D O I
10.3390/nu16203551
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and Aims: Metabolic liver disease is associated with obesity, insulin resistance, cardiovascular disease, and metabolic disorders. A Mediterranean diet (MD), known for its anti-inflammatory and antioxidant properties, is effective in managing various chronic diseases, including liver diseases. This study aimed to explore the influence of adherence to the MD on the risk of chronic metabolic diseases, including steatotic liver disease (SLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-related liver diseases (ALDs). Methods: This retrospective cohort study analyzed 5395 individuals from a single center between 2020 and 2022, grouped by adherence to the MD using the Korean Mediterranean Diet Adherence Score (K-MEDAS). MASLD score, ALD, and cardiovascular risk factors were also assessed. Statistical analyses were performed using 1:1 exact matching and multiple regression to compare the less adherent (K-MEDAS 0-7) and highly adherent (K-MEDAS 8-13) groups. Results: Adjusting for confounding variables, high adherence to the MD was significantly associated with lower rates of SLD (odds ratio [OR] 0.818, 95% confidence interval [CI] 0.700-0.957, p = 0.012), MASLD (OR 0.839, 95% CI 0.714-0.986, p = 0.033), and ALD (OR 0.677, 95% CI 0.671-0.683, p < 0.001). Post-propensity score matching analysis revealed that the highly adherent group exhibited significantly lower triglyceride levels, triglyceride and glucose index, atherogenic Index of Plasma, and Framingham risk scores than the less adherent group. Conclusions: Good adherence to the MD considerably reduces the risk of SLD, MASLD, and ALD, underscoring its protective effects and potential to prevent metabolic liver diseases and their complications.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] THE LIPIDOMIC PROFILE DISCRIMINATES BETWEEN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND COMBINED METABOLIC DYSFUNCTION- AND ALCOHOL-RELATED STEATOTIC LIVER DISEASE
    Schneider, Carolin Victoria
    Loomba, Rohit
    Huang, Helen
    Raptis, Anastasia
    Creasy, Kate Townsend
    Clusmann, Jan
    Van Haag, Felix
    Luedde, Tom
    Francque, Sven
    Schneider, Kai Markus
    HEPATOLOGY, 2024, 80 : S453 - S454
  • [2] Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)
    Wong, Robert J.
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):
  • [3] Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea
    Kwon, Yu-Jin
    Choi, Ja-Eun
    Hong, Kyung-Won
    Lee, Ji-Won
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [4] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [5] Characterizing alcohol-related and metabolic dysfunction-associated steatotic liver disease cirrhosis via fibrotic pattern analysis
    Fukushima, Masanori
    Miyaaki, Hisamitsu
    Nakao, Yasuhiko
    Sasaki, Ryu
    Haraguchi, Masafumi
    Takahashi, Kosuke
    Ozawa, Eisuke
    Miuma, Satoshi
    Akazawa, Yuko
    Soyama, Akihiko
    Eguchi, Susumu
    Okano, Shinji
    Nakao, Kazuhiko
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [6] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [7] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [8] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [9] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [10] Metabolic dysfunction-associated steatotic liver disease in adults
    不详
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):